Eagle Pharmaceuticals Stock Total Asset
| EGRX Stock | USD 4.19 0.10 2.44% |
Eagle Pharmaceuticals fundamentals help investors to digest information that contributes to Eagle Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eagle Stock. The fundamental analysis module provides a way to measure Eagle Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eagle Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 467.1 M | 490.4 M | |
| Intangibles To Total Assets | 0.36 | 0.21 |
Eagle | Total Asset |
Eagle Pharmaceuticals Company Total Asset Analysis
Eagle Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Eagle Pharmaceuticals Total Asset | 406.16 M |
Most of Eagle Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eagle Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eagle Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Eagle Pharmaceuticals is extremely important. It helps to project a fair market value of Eagle Stock properly, considering its historical fundamentals such as Total Asset. Since Eagle Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eagle Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eagle Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Eagle Total Asset Historical Pattern
Today, most investors in Eagle Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eagle Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eagle Pharmaceuticals total asset as a starting point in their analysis.
Eagle Pharmaceuticals Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Eagle Total Assets
Total Assets |
|
Based on the latest financial disclosure, Eagle Pharmaceuticals has a Total Asset of 406.16 M. This is 94.6% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 98.62% higher than that of the company.
Eagle Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eagle Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eagle Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eagle Pharmaceuticals by comparing valuation metrics of similar companies.Eagle Pharmaceuticals is currently under evaluation in total asset category among related companies.
Eagle Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Eagle Pharmaceuticals from analyzing Eagle Pharmaceuticals' financial statements. These drivers represent accounts that assess Eagle Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Eagle Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 826.4M | 627.8M | 664.6M | 378.1M | 340.3M | 500.4M | |
| Enterprise Value | 755.2M | 561.8M | 592.5M | 385.2M | 346.7M | 466.6M |
Eagle Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Eagle Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eagle Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eagle Pharmaceuticals' value.| Shares | Acadian Asset Management Llc | 2023-12-31 | 287.6 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 246.5 K | J. Goldman & Co Lp | 2023-12-31 | 246.4 K | Geode Capital Management, Llc | 2023-12-31 | 225.3 K | State Street Corporation | 2023-12-31 | 222.6 K | Two Sigma Advisers, Llc | 2023-12-31 | 222 K | Assenagon Asset Management Sa | 2023-12-31 | 217.7 K | Two Sigma Investments Llc | 2023-12-31 | 207.6 K | Bank Of America Corp | 2023-12-31 | 187 K | Blackrock Inc | 2023-12-31 | 984.9 K | Hhg Plc | 2023-12-31 | 775.5 K |
Eagle Fundamentals
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 110.22 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 87.22 % | ||||
| Number Of Shares Shorted | 1.18 M | ||||
| Price To Earning | 40.52 X | ||||
| Price To Book | 0.24 X | ||||
| Price To Sales | 0.23 X | ||||
| Revenue | 316.61 M | ||||
| Gross Profit | 221.67 M | ||||
| EBITDA | 65.48 M | ||||
| Net Income | 35.64 M | ||||
| Cash And Equivalents | 36.56 M | ||||
| Cash Per Share | 2.75 X | ||||
| Total Debt | 62.47 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 1.78 X | ||||
| Book Value Per Share | 19.25 X | ||||
| Cash Flow From Operations | 50.7 M | ||||
| Short Ratio | 7.01 X | ||||
| Earnings Per Share | 0.85 X | ||||
| Price To Earnings To Growth | 0.91 X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 134 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 53 M | ||||
| Total Asset | 406.16 M | ||||
| Retained Earnings | 111.5 M | ||||
| Working Capital | 77.67 M | ||||
| Current Asset | 119.05 M | ||||
| Current Liabilities | 35.45 M | ||||
| Net Asset | 406.16 M |
About Eagle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eagle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eagle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eagle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Eagle Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eagle Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eagle Stock
| 0.74 | EVOK | Evoke Pharma | PairCorr |
Moving against Eagle Stock
| 0.63 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.61 | ELYM | Eliem Therapeutics Trending | PairCorr |
| 0.51 | IBIO | Ibio Inc | PairCorr |
| 0.48 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.43 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Eagle Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eagle Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eagle Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eagle Pharmaceuticals to buy it.
The correlation of Eagle Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eagle Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eagle Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eagle Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Eagle Pharmaceuticals Piotroski F Score and Eagle Pharmaceuticals Altman Z Score analysis. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Eagle Stock analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share 0.85 | Revenue Per Share 19.684 | Quarterly Revenue Growth (0.13) | Return On Assets 0.0663 |
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.